Cargando…

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes. Currently there are no validated noninvasive diagnostics that can diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yi, Wadhawan, Samir, Greenfield, Alex, Decato, Benjamin E., Oseini, Abdul M., Collen, Rebecca, Shevell, Diane E., Thompson, John, Jarai, Gabor, Charles, Edgar D., Sanyal, Arun J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122380/ https://www.ncbi.nlm.nih.gov/pubmed/34027267 http://dx.doi.org/10.1002/hep4.1670

Ejemplares similares

Assessment of Variability in the SOMAscan Assay
por: Candia, Julián, et al.
Publicado: (2017)

Assessment of variability in the plasma 7k SomaScan proteomics assay
por: Candia, Julián, et al.
Publicado: (2022)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019)

SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients
por: Berrone, Elena, et al.
Publicado: (2023)

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
por: Luo, Yi, et al.
Publicado: (2021)

“Scanning” into the Future: The Promise of SOMAScan Technology for Kidney Disease
por: Coca, Steven G.
Publicado: (2018)

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
por: Luo, Yi, et al.
Publicado: (2018)

Proteomics Analysis of Cancer Exosomes Using a Novel Modified Aptamer-based Array (SOMAscan(TM)) Platform
por: Webber, Jason, et al.
Publicado: (2014)

Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH
por: Povero, Davide, et al.
Publicado: (2020)

SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients
por: Begic, Edin, et al.
Publicado: (2019)

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
por: Brown, Elizabeth A., et al.
Publicado: (2023)

Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform
por: George, Marc J., et al.
Publicado: (2020)

Cytokines IL-17, TNF and IFN-γ Alter the Expression of Antimicrobial Peptides and Proteins Disparately: A Targeted Proteomics Analysis using SOMAscan Technology
por: Altieri, Anthony, et al.
Publicado: (2018)

Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
por: Voyle, Nicola, et al.
Publicado: (2015)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
por: Loomba, Rohit, et al.
Publicado: (2020)

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013)

BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018)

Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis
por: Sivakumar, Pitchumani, et al.
Publicado: (2021)

MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
por: van Koppen, Arianne, et al.
Publicado: (2017)

A robust data-driven genomic signature for idiopathic pulmonary fibrosis with applications for translational model selection
por: Ammar, Ron, et al.
Publicado: (2019)

Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
por: Li, Xinlei, et al.
Publicado: (2023)

Insights into genetic variants associated with NASH-fibrosis from metabolite profiling
por: Mann, Jake P, et al.
Publicado: (2020)

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
por: Huisman, Tsipora M, et al.
Publicado: (2021)

CD4(+) T cell activation and inflammation in NASH-related fibrosis
por: Zhou, Yunfeng, et al.
Publicado: (2022)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

The plasma degradome reflects later development of NASH fibrosis after liver transplant
por: Li, Jiang, et al.
Publicado: (2023)

NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling
por: Sunami, Yoshiaki
Publicado: (2020)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
por: Clearfield, Elizabeth, et al.
Publicado: (2021)

Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death
por: Albadawy, Reda, et al.
Publicado: (2022)

Navigable networks as Nash equilibria of navigation games
por: Gulyás, András, et al.
Publicado: (2015)

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
por: McSweeney, Lorraine, et al.
Publicado: (2020)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jb39o5v3o4f0skn23up1l0vle1